| Completed | 3 | 201 | Europe, US, RoW | VGX-3100, Placebo, Electroporation (EP) | Inovio Pharmaceuticals | Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL | 07/20 | 04/21 | | |
| Completed | 3 | 203 | Europe, US, RoW | VGX-3100, Placebo, CELLECTRAâ„¢-5PSP | Inovio Pharmaceuticals | Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL | 08/22 | 09/22 | | |
ChiCTR2300071848: A Randomized, Double-blind, Placebo-Controlled Study in China to evaluate the efficacy and safety of VGX-3100 Delivered Intramuscularly (IM) followed by Electroporation with CELLECTRA™ 5PSP for the Treatment of HPV-16 and/or HPV-18 related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix |
|
|
| Recruiting | 3 | 84 | | 6 mg (1 ml) VGX-3100 intramuscular injection followed by EP with the CELLECTRA 5PSP device given at Day 1, Week 4 and Week 12 ;Placebo intramuscular injection followed by EP with the CELLECTRA 5PSP device given at Day 1, Week 4 and Week 12 | Chinese Academy of Medical Sciences Cancer Hospital; Beijing Apollo Saturn Biomedicine Technology Co. LTD, Beijing Apollo Saturn Biomedicine Technology Co. LTD | High Grade Squamous Intraepithelial Lesion of the Cervix | | | | |
